SCHEMBL7909484

SCHEMBL7909484

C[C@H](NC(=O)C1(c2ccccc2)CCNCC1)C(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
HDAC1 Q13547 1/20 0.49
OPRM1 P35372 2/20 0.49
TSHR P16473 2/20 0.48
ALOX15 P16050 1/20 0.48
TACR1 P25103 1/20 0.48
HDAC4 P56524 2/20 0.43
ATM Q13315 1/20 0.43
CTSL P07711 2/20 0.41
ROCK2 O75116 1/20 0.41
ITGA4 P13612 1/20 0.41
ITGB7 P26010 1/20 0.41
KHK P50053 1/20 0.40
THRB P10828 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7902182 0.86 ALDH1A1 (0.55) ALDH1A1HDAC1OPRM1TSHRALOX15
SCHEMBL6543233 0.86 ALDH1A1 (0.69) ALDH1A1HDAC1OPRM1TSHRALOX15
SCHEMBL3100018 0.82 ALDH1A1 (0.53) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL15200870 0.80 OPRM1 (0.54) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL6544545 0.78 OPRM1 (0.57) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL13092156 0.77 ALDH1A1 (0.51) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL7912225 0.77 ALDH1A1 (0.53) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL13092152 0.77 TACR1 (0.49) ALDH1A1HDAC1OPRM1TACR1ROCK2
Hydrochloric Acid SCHEMBL8348519 0.77 OPRM1 (0.56) ALDH1A1HDAC1OPRM1TACR1HDAC4
SCHEMBL13092155 0.76 OPRM1 (0.53) ALDH1A1HDAC1OPRM1TSHRTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 ALDH1A1 480/4885HDAC1 1713/4885OPRM1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.